Liminal BioSciences advances LMNL-6511: what it means for Liminal BioSciences stock

Liminal BioSciences' LMNL-6511 program is listed at Phase 1/2 in a September 18, 2026 diligence report, giving Liminal BioSciences stock a defined clinical development marker. The report identifies the asset as a small molecule drug targeting GPR84, a G-protein coupled receptor, and names Liminal BioSciences as both originator and active developer, according to PatSnap on September 18, 2026.

LMNL-6511 reaches Phase 1/2

The asset sits in early clinical development, with the reported highest global phase at Phase 1/2. Its stated biological focus is GPR84, while the broader disease footprint includes metabolic diseases and metabolic dysfunction-associated steatohepatitis, according to PatSnap.

The report also records one matched transaction under comparable GPR84 precedents. That transaction involved USD 13.00 million in upfront consideration, although the report identifies it as a 2017 comparable rather than a direct LMNL-6511 deal, making the figure a historical benchmark rather than company revenue.

Clinical evidence remains central

For investors, the key distinction is between development status and clinical proof. The September 18, 2026 report lists the program phase, but its transaction analysis frames clinical differentiation, safety, intellectual property and commercial economics as the main diligence gates, according to PatSnap.

Liminal BioSciences describes its business as development-stage biopharmaceutical research focused on novel small molecule therapeutics for metabolic, inflammatory and fibrotic diseases. Its website also presents a drug discovery platform and a pipeline of potential first-in-class and best-in-class candidates, according to Liminal BioSciences.

Stock identity and clinical benchmark

Onvista identifies the security under ticker PJ2 and classifies Liminal BioSciences within a diverse sector grouping, according to Onvista. The available company-specific benchmarks are therefore clinical: Phase 1/2 development for LMNL-6511 and the USD 13.00 million historical comparable transaction.